AstraZeneta's global CEO pay is "challenged."

's global CEO pay has been questioned again, with investors due to vote against it at its annual meeting at the end of the month. In addition, AZ's board's incentive bonus mechanism has been questioned by investors as at the back of calls from investment institutions. In 2019, CEO compensation of major pharmaceutical companies increased, and Roche, BMS and Teva declined.Investors at AstraZeneta have again questioned the pay of Pascal Soriot, its global chief executive, which has happened several times in the past few years, According to Fierce Pharma.Pension levels are being questionedSky News reports that investors in London-based investment institutions plan to vote against AZ's pay package at their annual meeting on April 29.The challenge is mainly about investors' dissatisfaction with Soriot's pension levels, referring to the average pension for UK workers.In 2019, Soriot's total net salary was 14.3 million pounds ($18.5 million), up about 26 percent from 11.36 million pounds ($14.73 million) the previous year, with a base salary of $2.142 million, long-term incentives and dividends of $7.497 million, and stock appreciation and dividends of $5.117 million, while Soriot's pension accounted for 30 percent of his total salary.AZ's board said in its compensation plan that it would cut its base salary to 20 per cent by 2020 based on investor feedback and gradually bring executive pensions into keeping levels in keeping with those of ordinary employees.But Sky News argues that under the compensation package, AZ's executive pay is still much higher than the average employee's. IVIS, the UK Investment Association's corporate governance research service provider, has issued AZ with a red alert for its pay policy, the highest warning, the News Channel has reported.The AZ board said the compensation package had the support of a majority of shareholders in the discussions, and Graham Chipchase, chairman of the remuneration committee, said it had received a high degree of satisfaction after discussions with 16 major shareholders.Global sales of some AstraZeneta drugs for 2017-2019 (US$100 million)Source: AstraZenecom's 2019 resultsIts results show that AZ achieved 12 percent sales growth in 2019, with total revenue of $24,384 million, up 10 percent from 2018. In terms of individual products, emerging products in areas such as
Oncology
, Cardiovascular and Respiratory have delivered significant growth, with its lung cancer-targeted drug Teriza the highest-selling product of 2019, growing by more than 70% annually from $900 million in 2017 to $3.19 billion in 2019. China's first PD-L1, approved at the end of 2019, also increased from $119 million in sales in 2017 to $1,469 million in 2019, an increase of more than 130 percent per year. New products such as the ovarian cancer-targeted drug Liptro and the diabetes inhibitor Andaltang have also achieved annual growth of more than 50%.Incentive bonuses have also been opposedand pensions are not the only items investors have questioned, and they are unhappy with the board's year-end bonus scheme for Soriot and the 550 per cent increase in long-term incentive bonuses from 500 per cent of wages to 550 per cent by 2020.In 2019, Soriot's year-end bonus is up to 150 per cent of his base salary. According to its AZ performance statistics, Soriot has helped the company achieve all but its underlying goals, with regulatory events, cash flow and total product sales reaching or exceeding the maximum threshold. Under the bonus scheme, Soriot's performance was awarded 142 per cent, while the board used its discretion to raise it to 150 per cent, a move that was met with displeasure by some investors.In terms of long-term incentives, AZ's board of directors said it was working to close the gap between the competitive global pharmaceutical
-talent
pool and market pay levels for the reasons for the increase in bonuses from 500 per cent to 550 per cent.The high-level pay regime offered to executives by AZ's board has been repeatedly questioned since 2014, despite news that Mr Soliot would leave AstraZeneta in 2017 for a double pay rise. 　　Sky News said the AZ board's move was inconsistent with calls by investment agencies to avoid the practice during the new crown virus epidemic. 　　Soriot is understood to have received repeated pay challenges from investors, with 40 per cent back in 2014 not supporting AZ's pay package and 31 per cent rejecting the proposed compensation package, and after Soriot successfully led AZ to reject Pfizer's bid, investors were concerned that its pay would be tied to a range of targets it set, including the controversial $40bn sales target for 2023. 　　Soriot's plan to raise bonuses by 68 per cent in 2017 received protests from 40 per cent of investors, and in 2018 he received 35 per cent of investors' complaints, even though he said his pay was down 34 per cent from the previous year and he was already the lowest-paid CEO in the
Pharmaceuticals
industry. 　　CEO of major pharmaceutical companies
pay inventory as the annual reports of major pharmaceutical companies are gradually published, their CEO pay has also attracted much attention. 　　Alex Gorsky, Chief Executive Officer of Johnson and Johnson, received a total compensation package of $25.37 million, up 26.9 per cent from 2018, notably due to pension increases. 　　In 2019, Amjin's sales fell about 2 percent, but its CEO's annual salary increased, with a total compensation of $19.6 million, up 10 percent from 2018, but its incentive bonus fell by more than $550,000. 　　After Merck lifted the retirement age, Ken Frazier continued to serve as CEO, earning a total of $27.65 million in 2019, thanks to a series of targets that Merck met in 2019, a $15.93 million stock and options award, and a $4.61 million incentive bonus, up more than 50 percent from the year before, thanks to better-than-expected K-drug revenue. 　　Richard Gonzalez, AbbVie's chief executive, has earned $21.62 million a year and his pension has increased by nearly $3 million, despite a 1.6 percent increase in 2019. 　　Notably, Pfizer President Albert Bourla, as the new CEO, earns $17.9 million a year in 2019, up 82.1 percent from his former company's total annual salary. One reason for the over-fulfillment target is that Pfizer achieved revenue of $52.4 billion in 2019, exceeding the board's target of $3 billion and cash flow reaching $12.9 billion, exceeding the benchmark of $1.3 billion. Bourla received a long-term incentive bonus of $3.63 million on the strength of the performance. 　　Roche President Severin Schwan's total compensation fell about 2.2 percent after a surge in CEO pay, and his PSP award fell to zero from $1.532 million a year earlier. 　　Giovanni Caforio, BMS's chief executive, also had a decline in total compensation as the board adjusted its executive compensation package, and its stock awards fell slightly, from $19.4 million to $18.8 million, while base pay was the same as the previous year. 　　Lilly, Novaral, GSK's CEO's annual salary also ushered in an increase of nearly 15% to 40%, after growth of about $20 million, and after a series of adjustments, Teva's adjusted CEO's annual salary fell by $20 million. 　　According to E pharmaceutical managers previously statistics, in 2018 A-share, Hong Kong-share pharmaceutical listed company executives overall package compensation of more than 5 people, including baiji Shenzhou's two founders, Keshi Pharmaceuticals CEO Jiang Ningjun and Xinda Bio CEO Yu Dechao. The CEO of Pharmaceuticals Mingkangde, China Bio, Meirui Medical, Fosun Pharma and other companies has also earned more than 10 million yuan a year. 　　Compared with the previous E drug manager statistics of domestic salary of more than 10 million pharmaceutical CEO, from the current published annual report, Meirui Medical, Pharmaceutical Mingkangde and other companies in 2019 CEO annual salary is also more than 10 million yuan. (E drug manager)